Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) Research & Development (2021 - 2025)

InMed Pharmaceuticals (INM) has 5 years of Research & Development data on record, last reported at $630636.0 in Q4 2025.

  • For Q4 2025, Research & Development fell 29.55% year-over-year to $630636.0; the TTM value through Dec 2025 reached $2.5 million, down 15.12%, while the annual FY2025 figure was $2.9 million, 11.3% down from the prior year.
  • Research & Development reached $630636.0 in Q4 2025 per INM's latest filing, up from $581612.0 in the prior quarter.
  • Across five years, Research & Development topped out at $2.5 million in Q4 2021 and bottomed at $112720.0 in Q2 2025.
  • Average Research & Development over 5 years is $1.0 million, with a median of $864829.5 recorded in 2022.
  • The widest YoY moves for Research & Development: up 74.47% in 2025, down 82.89% in 2025.
  • A 5-year view of Research & Development shows it stood at $2.5 million in 2021, then plummeted by 66.44% to $851356.0 in 2022, then dropped by 28.37% to $609791.0 in 2023, then soared by 46.8% to $895176.0 in 2024, then fell by 29.55% to $630636.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Research & Development were $630636.0 in Q4 2025, $581612.0 in Q3 2025, and $112720.0 in Q2 2025.